Rafael Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 25, 2025, reports the completion of a business combination between Rafael Holdings, Inc. ("Rafael") and Cyclo Therapeutics, Inc. ("Cyclo"). The transaction was executed via a two-step merger agreement originally dated August 21, 2024, and subsequently amended. Following the merger, Cyclo was dissolved, and its operations were integrated into Rafael.
Key Financial Metrics and Transaction Details
The filing details the equity consideration issued to Cyclo shareholders rather than traditional operating metrics for the period.
- Shares Issued: Rafael issued approximately 7,132,228 shares of Class B common stock in connection with the Merger.
- Exchange Ratio: Each outstanding share of Cyclo common stock was converted into 0.3525 shares of Rafael Class B common stock.
- Options Conversion: Outstanding Cyclo options were converted into options to acquire 618,702 shares of Rafael Class B common stock.
- Warrants: Publicly traded Cyclo warrants were converted into 1,078,796 warrants to purchase 380,253 shares of Rafael Class B common stock.
- Trading Status: Cyclo common stock (symbol "CYTH") was suspended from trading on the Nasdaq Capital Market as of the close of trading on March 25, 2025.
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Pro forma financial information is incorporated by reference from a prior proxy statement and will be updated in a future amendment.
Material Changes
The primary material change is the structural consolidation of Cyclo Therapeutics into Rafael Holdings. This results in:
- The delisting of Cyclo from the Nasdaq Capital Market.
- An increase in Rafael's outstanding share count by approximately 7.1 million shares.
- The expansion of Rafael's Board of Directors from five to six members.
Outlook, Management Commentary, and Risks
Management Changes: Markus W. Sieger, former Chairman of Cyclo, was appointed to the Rafael Board of Directors effective March 25, 2025. He is considered an independent director and will receive compensation consistent with other non-employee directors.
Regulatory and Listing Status: The newly issued Rafael warrants are expected to begin trading on the NYSE American on or about March 31, 2025, pending approval.
Financial Reporting Contingencies: Financial statements of the acquired business (Cyclo) and updated pro forma financial information are not included in this filing. Rafael intends to file these documents by amendment no later than 71 calendar days after the filing date of this report.
Key Facts for Investor Verification
- Verify the exact number of shares issued (7,132,228) and the impact on dilution for existing Rafael shareholders.
- Confirm the listing approval and trading commencement date for the new Rafael warrants on the NYSE American (expected March 31, 2025).
- Monitor the upcoming amendment to this 8-K (due within 71 days) for the required financial statements of Cyclo and updated pro forma data.
- Review the Merger Agreement (Exhibit 2.1) for specific terms regarding the conversion of warrants and options not fully detailed in the summary.